Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia

American Journal of Hematology

Volumn 89, Issue 6, 2014, Pages 604-609

  Cervera, Nathalie ^a,b   Itzykson, Raphael ^c,d   Coppin, Emilie ^a,b   Prebet, Thomas ^a,b,e   Murati, Anne ^a,b,e   Legall, Stevan ^f   Vey, Norbert ^a,b,e   Solary, Eric ^c,d   Birnbaum, Daniel ^a,b   Gelsi Boyer, Véronique ^a,b,e  

^a AIX MARSEILLE UNIVERSITY   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f centre hospitalier de Gap   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; PROTEIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; SF3B1 PROTEIN; SRSF2 PROTEIN; SUZ12 PROTEIN; TET2 PROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; DNA METHYLATION; DNA SPLICING; FOLLOW UP; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CORE BINDING FACTOR ALPHA 2 SUBUNIT; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MUTATION; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84900867793     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23702     Document Type: Article

References (38)

1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009;114:937-951.
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
4. Bennett JM, Catovsky D, Daniel MT, et al. The chronic myeloid leukaemias: Guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 1994;87:746-754.
5. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 1999;111:S8-S12.
6. Dunbar AJ, Gondek LP, O'Keefe CL, et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008;68:10349-10357.
7. Boultwood J, Perry J, Zaman R, et al. High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. Leukemia 2010;24:1139-1145.
8. Yi JH, Huh J, Kim HJ, et al. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment. Ann Hematol 2013;92:459-469.
9. Itzykson R, Kosmider O, Renneville A, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood 2013;121:2186-2198.
10. Gelsi-Boyer V, Trouplin V, Adélaïde J, et al. Genome profiling of chronic myelomonocytic leukemia: Frequent alterations of RAS and RUNX1 genes. BMC Cancer 2008;8:299-213.
11. Kosmider O, Gelsi-Boyer V, Ciudad M, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009;94:1676-1681.
12. Gelsi-Boyer V, Trouplin V, Adélaïde J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009;145:788-800.
13. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011;478:64-69.
14. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012;120:3080-3088.
15. Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31:2428-2436.
16. Gelsi-Boyer V, Cervera N, Bertucci F, et al. Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. Haematologica 2013;98:576-583.
17. Gelsi-Boyer V, Trouplin V, Roquain J, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol 2010;151:365-375.
18. Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 2010;24:1094-1096.
19. Murati A, Brecqueville M, Devillier R, et al. Myeloid malignancies: Mutations, models and management. BMC Cancer 2012;12:304-319.
20. Kuo MC, Liang DC, Huang CF, et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia 2009;23:1426-1431.
21. Such E, Germing U, Malcovati L, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood 2013;121:3005-3015.
22. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088. Erratum in: Blood 1998;91:1100.
23. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-2465.
24. Fenaux P, Beuscart R, Lai JL, et al. Prognostic factors in adult chronic myelomonocytic leukemia: An analysis of 107 cases. J Clin Oncol 1988;6:1417-1424.
25. Germing U, Kündgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004;45:1311-1318.
26. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-1361.
27. Stark AN, Thorogood J, Head C, et al. Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML). Br J Cancer 1987;56:59-63.
28. Fenaux P, Beuscart R, Lai JL, et al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 1988;6:1417-1424.
29. Storniolo AM, Moloney WC, Rosenthal DS, et al. Chronic myelomonocytic leukemia. Leukemia 1990;4:766-770.
30. Catalano L, Improta S, de Laurentiis M, et al. Prognosis of chronic myelomonocytic leukemia. Haematologica 1996;81:324-329.
31. Nösslinger T, Reisner R, Grüner H, et al. Dysplastic versus proliferative CMML-A retrospective analysis of 91 patients from a single institution. Leuk Res 2001;25:741-747.
32. Onida F. Pronostics factors in chronic myelomonocytic leukemia: A retrospective analysis of 213 patients. Blood 2002;99:840-849.
33. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-2506.
34. Ricci C, Fermo E, Corti S, et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res 2010;16:2246-2256.
35. Kohlmann A, Grossmann V, Klein HU, et al. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 2010;28:3858-3865.
36. Parikh C, Subrahmanyam R, Ren R. Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice. Blood 2006;108:2349-2357.
37. Lee BH, Tothova Z, Levine RL, et al. FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia. Cancer Cell 2007;12:367-380.
38. Wang J, Liu Y, Li Z, et al. Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. Blood 2010;116:5991-6002.